



[Home](#) / [Investors](#) / [News Releases](#)

# Insmed to Present Cancer Data to CaP Cure, the Prostate Cancer Foundation

Insmed to Present Cancer Data to CaP Cure, the Prostate Cancer Foundation

RICHMOND, Va.--(BUSINESS WIRE)--Nov. 5, 2003--Insmed Incorporated (Nasdaq:INSM) announced today that the Company will present to the 10th Annual Scientific Retreat of the Prostate Cancer Foundation, formerly known as CaP CURE, to be held November 8-10, 2003 at the Marriott Marquis, New York. Insmed will present its preclinical findings to date supporting the use of its proprietary compound, recombinant human insulin-like growth factor binding protein-3, rhIGFBP-3, as a novel anti-tumor agent.

Dr. Laura Shiry, lead scientist responsible for managing the IGFBP-3 program commented, "We are quite honored to have been invited to present to this prestigious event. The Prostate Foundation has forged alliances with the world's leading pharmaceutical and biotechnology companies. The Foundation plays a crucial role in increasing the awareness and commitments of prostate cancer research."

## IGFBP-3: A Naturally Occurring Anti-Cancer Agent

Our proprietary product, rhIGFBP-3, is a protein that is normally found in our bloodstream that has been shown to induce cancer cell death in a variety of experimental systems. Several studies have demonstrated that cancer risk increases with decreasing levels of circulating IGFBP-3. In addition, recent independent studies have demonstrated that IGFBP-3 can induce cell cycle arrest and enhance the efficacy of chemotherapeutic agents. Insmed is currently engaged in an active preclinical program with leading clinical oncologists and world experts in the field of IGFBP-3 research to evaluate the efficacy of rhIGFBP-3 as a therapeutic agent and to define the optimal clinical protocol in which to translate these promising observations into human clinical trials.

## About The Prostate Cancer Foundation

Formerly known as CaP CURE, the Prostate Cancer Foundation (the Foundation) is the world's largest private source of prostate cancer research funding. Since its inception in 1993, the Foundation has awarded more than \$104 million to fund 1,000 medical research projects worldwide. The Foundation was founded with an urgent mission: identify and support prostate cancer research that will rapidly translate into treatments and cures. Together with survivors, scientists and advocates, the Foundation has established a system that encourages collaboration, reduces bureaucracy and speeds the process of discovery. The Prostate Cancer Foundation reaches out to private industry, the patient advocacy community and government research institutions. These partnerships provide a model to speed the cure for prostate cancer - and all cancers. For more information about the Foundation please visit, [www.prostatecancerfoundation.org](http://www.prostatecancerfoundation.org).

## About Insmed

Insmed Incorporated develops pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical needs. The Company's most advanced product candidate, the rhIGF-I/rhIGFBP-3 complex is a novel delivery composition of IGF-I that regulates essential metabolic and anabolic (growth promoting) processes, such as glucose uptake and tissue regeneration. Insmed is developing the rhIGF-I/rhIGFBP-3 complex for the treatment of Growth Hormone Insensitivity Syndrome (GHIS) and both type 1 and type 2 diabetes. The Company's second product candidate, rhIGFBP-3, is a recombinant protein that is being developed as an anti-cancer agent targeted towards the inhibition of solid tumor growth. Further information is available at the company's corporate website: [www.insmed.com](http://www.insmed.com)

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations,

cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.

CONTACT: Insmed Incorporated  
Baxter Phillips, III, 804-565-3041; [bphillips@insmed.com](mailto:bphillips@insmed.com)

---